Treatment | Page 18 of 465 | SpiritIndia.com

Folic Acid :: Folic Acid Lowers Blood Arsenic Levels in Bangladesh

A new study conducted in Bangladesh finds that folic acid supplements can dramatically lower blood arsenic levels in individuals chronically exposed to arsenic-contaminated drinking water. Arsenic is a toxic element that is naturally present in some soils and water. Arsenic-contaminated drinking water is currently a significant public health problem in at least 70 countries, including several developing countries and also parts of the United States.

HIV :: National Latino AIDS Awareness Day, October 15, 2007

October 15, 2007, marks the fifth annual National Latino AIDS Awareness Day. On this day, the National Institute of Allergy and Infectious Diseases (NIAID) pledges to continue working toward reducing the burden of HIV/AIDS in the Latino community in the United States.

Mental Health :: Ban Ki-moon calls for scaling up resources for mental health services

More than 60 per cent of people globally who suffer from mental disorders are not receiving treatment, Secretary-General Ban Ki-moon said today, urging an increase in resources devoted to mental health care.

Medicaid :: Patients in Medicaid managed care programs may receive lower-quality care than commercial programs

Medicaid managed care enrollees appear to receive lower-quality care than patients enrolled in commercial managed care programs, according to a study in the Oct. 10 issue of JAMA.

Weight Loss :: Programs show short-term benefits in helping children maintain weight loss

Children who lost weight were able to keep it off more effectively by participating in maintenance treatment programs that emphasized behavioral skills or social facilitation, although the effectiveness lessened over time, according to a study in the Oct. 10 issue of JAMA.

Alcohol :: Medication shows promise as a treatment for alcohol dependence

Alcohol-dependent patients who received the medication topiramate had fewer heavy drinking days, fewer drinks per day and more days of continuous abstinence than those who received placebo, according to a study in the Oct. 10 issue of JAMA.

Cancer :: GSK & Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology

GlaxoSmithKline (GSK) and Synta Pharmaceuticals Corp. announced the execution of a global collaboration agreement for the joint development and commercialisation of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.

Ovarian Cancer :: Early warning symptoms of ovarian cancer identified in CDC/Thomson healthcare study

In a study published in the Journal of Women’s Health, researchers from the Centers for Disease Control and Prevention and Thomson Healthcare (NYSE: TOC; TSK: TOC) found a distinct pattern of medical signs and symptoms that occurred prior to the detection of ovarian cancer.

Prostate Cancer :: IMRT better for sparing bladder when treating prostate cancer

When treating early-stage prostate cancer, intensity modulated radiation therapy spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy , but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Epilepsy :: FDA approves first generic anticonvulsant drug Trileptal

The U.S. Food and Drug Administration approved the first generic versions of Trileptal (oxcarbazepine), an anticonvulsant drug. Generic oxcarbazepine is FDA-approved for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged four years and above.